The investment firm Roth Capital was out with a research report on Cytori Therapeutics Inc (NASDAQ:CYTX), following the news that the company's regenerative cell technology system, Celution, has …
As the biotech sector becomes more volatile, analyst Joseph Pantginis of Roth Capital points out that it is increasingly necessary to “focus on names with …
Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Can-Fite BioPharma Ltd (NYSEMKT:CANF) with a price target of $20, after the company signed …
Roth Capital’s healthcare analyst Joseph Pantginis weighed in today with a few insights on ImmunoCellular Therapeutics Ltd (NYSE MKT:IMUC), after the company reported full-year 2014 results, posting EPS of …
In a research report issued today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Cytori Therapeutics Inc (NASDAQ:CYTX) with a $6 price …
Roth Capital analyst Joseph Pantginis maintained a Buy rating on Galena Biopharma (NASDAQ:GALE) with an $8.00 price target, after the company reported its FY2014 financial …
Roth Capital’s healthcare analyst Joseph Pantginis weighed in with a few insights on MEI Pharma (NASDAQ:MEIP), after the company provided an update from its MEI-004 Phase II study …
Keryx Biopharmaceuticals (NASDAQ:KERX) received more attention from analysts at Roth Capital. The research team, led by analyst Joseph Pantginis, reiterated a Buy rating on the stock with a …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) received another set of praises from analysts at Roth Capital, in addition to analysts at Cowen and Brean Capital.
Roth Capital’s healthcare analyst Joseph Pantginis weighed in with a few insights on Cytori Therapeutics Inc (NASDAQ:CYTX), as the company announced that the first patient has been …
